Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis

AbstractAs the first targeted systemic agent for the treatment of moderate to severe atopic dermatitis (AD), dupilumab represents a novel therapeutic opportunity for both patients and providers. However, a subset of patients receiving dupilumab are either partial responders who exhibit some improvement in Investigator ’s Global Assessment score but not sufficient to meet the primary endpoint, or are non-durable responders who achieve therapeutic endpoint with subsequent partial loss of efficacy. We propose a therapeutic algorithm for the management of dupilumab partial responders and non-durable responders that involves maximizing topical therapy, seeking alternative diagnoses, and using dupilumab in conjunction with traditional systemic immunosuppressive agents. With a number of targeted agents for AD in the drug development pipeline, we encourage patients who do not have an adequate response to dupiluma b to remain patient and optimistic as the arsenal of AD treatment modalities continues to expand.

Source: American Journal of Clinical Dermatology - March 26, 2019 Category: Dermatology Source Type: research